Second-line chemotherapy yields a poor response rate of 9.4% in advanced synovial sarcoma, highlighting an urgent need for novel therapeutic regimens.
Our exploratory study revealed that the response rate of second-line chemotherapy regimens for patients with SS was 9.4%. Therefore, there is an urgent need to develop more active therapeutic regimens for SSs.
Kojima et al. (Sat,) studied this question.